GlassScriptPhysician profile
James T Methvin
NPI 1770535734
$11,430.41
in general payments reported to CMS, 2019-2025
14 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $59.72 · 2021: $282 · 2022: $118 · 2023: $157 · 2024: $112 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291 · Education: $99.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.22 |
| Education | $99.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,778.80 | 2019-2025 | Da Vinci Surgical System |
| Kerecis Limited | $145.52 | 2020-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Davol INC. | $108.08 | 2021 | |
| Myriad Genetic Laboratories, INC. | $92.38 | 2021-2025 | Myrisk |
| Smith+Nephew, INC. | $84.34 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $57.71 | 2021 | |
| Stryker Corporation | $37.67 | 2025 | Molli |
| Ivantis, INC | $35.00 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $20.94 | 2025 | |
| Sanara Medtech INC. | $17.39 | 2022 | |
| Boston Scientific Corporation | $17.02 | 2024 | Spyglass Discover |
| Polynovo North America LLC | $15.22 | 2022 | |
| Tactile Systems Technology INC | $11.12 | 2019 | |
| Medela LLC | $9.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Methvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.